97. 潰瘍性大腸炎 Ulcerative colitis Clinical trials / Disease details
臨床試験数 : 2,527 / 薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02073526 (ClinicalTrials.gov) | May 2013 | 9/1/2014 | Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease | Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease | Inflammatory Bowel Disease;Crohn's Disease;Ulcerative Colitis | Drug: Infliximab, adalimumab, certolizumab pegol | Oslo University Hospital | NULL | Completed | 18 Years | N/A | Both | 1230 | N/A | Norway |
| 2 | NCT01090154 (ClinicalTrials.gov) | December 1, 2010 | 15/3/2010 | Certolizumab Pegol for the Treatment of Moderate to Severe Ulcerative Colitis: An Open Label Study | Certolizumab Pegol for the Treatment of Moderate to Severe Ulcerative Colitis: An Open Label Study | Ulcerative Colitis | Drug: Cimzia | University of Washington | UCB Pharma;University of Pennsylvania | Completed | 18 Years | 75 Years | All | 27 | Phase 2 | United States |